ANTHONY P ADAMIS, M.D.
Medical Practice in New York, NY
License number
New York 70514
Category
Medical Practice
Type
Ophthalmology
Address
Address
2
3 Flr, New York, NY 10036
12 Sunnybrae Pl, Yonkers, NY 10708
12 Sunnybrae Pl, Yonkers, NY 10708
Phone
(212) 824-3100
Personal information
See more information about ANTHONY P ADAMIS at radaris.comName
Address
Phone
42 Josephine Ave, Kingston, NY 12401
12 Sunnybrae Pl #ACE, Bronxville, NY 10708
54 Tivoli Gdns, Tivoli, NY 12583
Professional information
See more information about ANTHONY P ADAMIS at trustoria.com
Anthony P Adamis, New York NY
Anthony P Adamis, New York NY
Specialties:
Ophthalmologist
Address:
3 Times Sq, New York, NY 10036
Education:
University of Chicago, Pritzker School of Medicine - Doctor of Medicine
Massachusetts Eye & Ear Infirmary - Fellowship - Cornea and External Diseases
University of Michigan Health System - Residency - Ophthalmology
Massachusetts Eye & Ear Infirmary - Fellowship - Cornea and External Diseases
University of Michigan Health System - Residency - Ophthalmology
Board certifications:
American Board of Ophthalmology Certification in Ophthalmology
Ceo At Jerini Ophthalmic
Ceo At Jerini Ophthalmic
Position:
CEO at Jerini Ophthalmic
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Jerini Ophthalmic
-
CEO
Eyetech Pharmaceuticals
2002 - 2005
-
CSO
Methods And Compositions For Treating Macular Degeneration
Methods And Compositions For Treating Macular Degeneration
US Patent:
2007002, Feb 1, 2007
Filed:
Jul 24, 2006
Appl. No.:
11/491819
Inventors:
David Guyer - New York NY, US
Anthony Adamis - Bronxville NY, US
Denis O'Shaughnessy - Mendham NJ, US
Anthony Adamis - Bronxville NY, US
Denis O'Shaughnessy - Mendham NJ, US
International Classification:
A61K 48/00
US Classification:
514044000
Abstract:
This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD.
Methods For Treating Ocular Neovascular Diseases
Methods For Treating Ocular Neovascular Diseases
US Patent:
2007002, Feb 1, 2007
Filed:
Jul 24, 2006
Appl. No.:
11/491818
Inventors:
David Guyer - New York NY, US
Anthony Adamis - Bronxville NY, US
Denis O'Shaughnessy - Mendham NJ, US
Anthony Adamis - Bronxville NY, US
Denis O'Shaughnessy - Mendham NJ, US
International Classification:
A61K 48/00
US Classification:
514044000
Abstract:
Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy.
Transscleral Drug Delivery Device And Related Methods
Transscleral Drug Delivery Device And Related Methods
US Patent:
2006016, Jul 27, 2006
Filed:
Feb 17, 2004
Appl. No.:
10/545726
Inventors:
Anthony Adamis - Bronxville NY, US
Joan Miller - Winchester MA, US
Mark Mescher - West Newton MA, US
Evangelos Gragoudas - Lexington MA, US
Jeffrey Borenstein - Holliston MA, US
Joan Miller - Winchester MA, US
Mark Mescher - West Newton MA, US
Evangelos Gragoudas - Lexington MA, US
Jeffrey Borenstein - Holliston MA, US
International Classification:
A61M 31/00
US Classification:
604500000
Abstract:
The invention provides a low-profile, dome-shaped body for attachment to a scleral surface of an eye and defining an internal cavity for receiving a drug or other pharmaceutically active agent. The device has an opening for controllably delivering the drug into the eye at therapeutically effective concentrations over a prolonged period of time. When attached, the device does not affect or otherwise restrict movement of the eye. Features of the invention include an optional drug inlet port and puncture guard, both designed for refilling the device while preventing a needle inserted through the inlet port from contacting the sclera.
Combination Therapy For The Treatment Of Neovascular Disorders
Combination Therapy For The Treatment Of Neovascular Disorders
US Patent:
2009009, Apr 16, 2009
Filed:
Jan 30, 2007
Appl. No.:
11/699825
Inventors:
Barrett Katz - New York NY, US
Matthew Feinsod - Great Neck NY, US
David T. Shima - Herts, GB
Anthony P. Adamis - Bronxville NY, US
Matthew Feinsod - Great Neck NY, US
David T. Shima - Herts, GB
Anthony P. Adamis - Bronxville NY, US
International Classification:
A61K 39/395
US Classification:
4241451, 4241721
Abstract:
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a combination of VEGF antagonists to the patient. The invention also features a pharmaceutical composition containing a first VEGF antagonist and a second VEGF antagonist for the treatment or prevention of a neovascular disorder.
Methods And Compositions For Treating Ocular Disorders
Methods And Compositions For Treating Ocular Disorders
US Patent:
2006029, Dec 28, 2006
Filed:
Jun 22, 2006
Appl. No.:
11/472761
Inventors:
Anthony Adamis - Bronxville NY, US
David Guyer - New York NY, US
Marlene Modi - Monmouth Junction NJ, US
David Guyer - New York NY, US
Marlene Modi - Monmouth Junction NJ, US
International Classification:
A61K 48/00
US Classification:
514044000
Abstract:
This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease.
Treatment Of Ocular Disorders
Treatment Of Ocular Disorders
US Patent:
7419666, Sep 2, 2008
Filed:
Feb 23, 2005
Appl. No.:
11/064058
Inventors:
Eirini Iliaki - Boston MA, US
Anthony P. Adamis - Bronxville NY, US
Joan W. Miller - Winchester MA, US
Evangelos S. Gragoudas - Lexington MA, US
Anthony P. Adamis - Bronxville NY, US
Joan W. Miller - Winchester MA, US
Evangelos S. Gragoudas - Lexington MA, US
Assignee:
Massachusetts Eye and Ear Infirmary - Boston MA
International Classification:
A61K 39/395, C07K 16/28
US Classification:
4241441, 4241301, 4241431, 5303871, 53038822
Abstract:
The invention includes a method of treating an intraocular disorder in a mammal, the method comprising administering to the mammal a Very Late Antigen-4 (VLA-4) antagonist for the treatment of selected ocular disorders.
Vegf Variants
Vegf Variants
US Patent:
2006028, Dec 21, 2006
Filed:
Apr 28, 2006
Appl. No.:
11/414724
Inventors:
David Shima - Barnet, GB
Anthony Adamis - Bronxville NY, US
Gregory Robinson - Wilmington MA, US
Yin-Shan Ng - North Billerica MA, US
Kazuaki Nishijima - Arlington MA, US
Dominik Krilleke - Arlington MA, US
Anthony Adamis - Bronxville NY, US
Gregory Robinson - Wilmington MA, US
Yin-Shan Ng - North Billerica MA, US
Kazuaki Nishijima - Arlington MA, US
Dominik Krilleke - Arlington MA, US
International Classification:
C07K 14/475, C07H 21/04, C12P 21/06, A61K 38/18
US Classification:
435069100, 514012000, 435320100, 435325000, 530399000, 536023500
Abstract:
Applicants have defined the pro-inflammatory domain of the Vascular Endothelial Growth Factor VEGF164(165) protein molecule using VEGF164 protein mutants in which the heparin binding domain is inactivated through alanine scanning, site directed mutagenesis. The invention provides novel VEGF variants having a modified heparin binding domain. The VEGF variants modified heparin binding function compared to native VEGF while maintaining receptor binding function. The invention provides compositions and methods for treating disorders relating to angiogenesis and inflammation.